Home・Список акций・Lantheus Holdings Inc

Lantheus Holdings Inc

Закрыт

СекторЗдравоохранение

100.52 -0.25

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

100.52

Макс.

101.27

Ключевые показатели
By Trading Economics
Доход	75M 193M
Продажи	11M 388M
P/E Средняя по отрасли	23.943 57.366
Прибыль на акцию	1.32
Рентабельность продаж	49.834
Сотрудники	1,193
EBITDA	-69M 115M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+4.56% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-8.6M 6.6B
Предыдущая цена открытия	100.77
Предыдущая цена закрытия	100.52

Новостные настроения

By Acuity

47%

53%

158 / 340 Рейтинг в Healthcare

Lantheus Holdings Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 авг. 2026 г., 19:36 UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

19 авг. 2026 г., 23:26 UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

13 авг. 2026 г., 20:06 UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

12 авг. 2026 г., 23:36 UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

3 авг. 2026 г., 19:56 UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

31 июл. 2026 г., 22:01 UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

30 июл. 2026 г., 17:31 UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

29 июл. 2026 г., 21:42 UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

28 июл. 2026 г., 19:42 UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

27 июл. 2026 г., 22:51 UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

24 июл. 2026 г., 22:01 UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

23 июл. 2026 г., 23:02 UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

22 июл. 2026 г., 19:06 UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

21 июл. 2026 г., 22:46 UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

20 июл. 2026 г., 19:46 UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Сравнение c конкурентами

Изменение цены

Lantheus Holdings Inc Прогноз

Целевая цена

By TipRanks

4.56% рост

Прогноз на 12 месяцев

Средняя 105.4 USD 4.56%

Максимум 115 USD

Минимум 102.5 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Lantheus Holdings Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

10 ratings

Покупка

Удержание

Продажа

Основано на мнении 10 аналитиков, присваивавших рейтинги акциям Lantheus Holdings Inc – Данные за последние 3 месяца.

Настроения

By Acuity

158 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.